AGY – Allergy Therapeutics plc
Allergy Therapeutics (LSE:AGY) ended a bruising few years on a firmer footing. In a trading update released on 29 July 2026, the Worthing-based allergy specialist told the market that revenue for the year to 30 June 2026 is expected to reach roughly £59.9m, up about 9% on a reported basis, with second-half sales accelerating to £23.6m, more than 12% ahead of the same period a year earlier. Just as important for a company whose shares have spent much of the past year under pressure, management pointed forward, guiding to double-digit revenue growth in the new financial year to June 2027.
The combination matters because it frames FY2026 as a turning point rather than a destination. After a period defined by supply disruption, regulatory upheaval in its largest market and repeated recourse to shareholder funding, the group is now presenting a picture of stabilised operations, a freshly launched flagship product and a refinanced balance sheet. Whether that momentum proves durable is the central question for investors weighing the stock.
The business
Allergy Therapeutics (LSE:AGY) develops and sells allergen-specific immunotherapy, treatments that aim to retrain the immune system rather than simply damp down symptoms. Founded in 1998 and listed on London's AIM under the ticker AGY, the group employs several hundred staff and sells across Europe, with Germany, Spain, Austria, Italy, the Netherlands and Switzerland among its principal markets.
Its commercial range includes the Pollinex Quattro short-course pollen therapy alongside Oralvac, Venomil and Acarovac products spanning grass, tree, house-dust-mite and venom allergies. Behind the marketed portfolio sits a development pipeline that has long been the equity story's more speculative leg, including the VLP Peanut short-course peanut vaccine and the grass pollen programme that has now reached the market in Germany.
Behind the headline
The event driving sentiment is the year-end trading update, which followed hard on the heels of a corporate governance change: on 28 July 2026 the company announced the appointment of an executive chairman, and a day later set out its revenue expectations for the period just closed.
The strategic centrepiece is Grassmuno, described as the first subcutaneous grass pollen immunotherapy approved under Germany's TAV regime. Marketing authorisation was granted in December 2025 and the product launched mid-season in January 2026. Because grass pollen treatment is seasonal, FY2026 captured only a partial contribution; management's case for accelerating growth rests heavily on Grassmuno entering its first full peak treatment season in the year ahead.
The financial picture
On the numbers guided, the full-year figure of about £59.9m compares with £55.0m in the prior year, a reported advance of roughly 9%. The company also flagged a return to double-digit growth on a gross revenue basis before rebates, with the reported figure held back by currency and rebate effects; constant-currency growth was more modest, in the mid-single digits.
The shape of the year is instructive. First-half revenue of £36.3m for the six months to 31 December 2025 was up 7% reported, with Germany's registered portfolio recovering as the market transitions away from previously unregistered products under the TAV programme. The second half then quickened, with Spain a notable bright spot. Cash told a similar story of repair: the group closed the year with £24.2m, up from £12.8m a year earlier and well above the £10.1m held at the December half-year, though that improvement owes much to financing rather than operating cash generation.
Comparison with earlier periods
Context is important here. The prior two years were shaped by supply-chain problems and the German regulatory transition, which together suppressed sales and stretched the balance sheet. Set against that backdrop, a return to reported growth and an accelerating second half represent a meaningful directional change rather than a step-change in scale; revenue remains below the levels the group reported before its difficulties. On our reading, FY2026 is best understood as the year the decline was arrested and the base rebuilt.
Strategy and growth drivers
The forward case rests on three planks. First, Grassmuno's first full season, which management expects to be the primary engine of double-digit growth in FY2027. Second, the phased conclusion of Germany's TAV transition, due in October 2026, which should remove a persistent headwind as unregistered products give way to authorised ones. Third, continued momentum in Spain and the broader registered portfolio.
Beyond the near term, the pipeline offers optionality. The PROTECT trial met its primary safety endpoint in December 2025, and the VLP Peanut programme remains the group's most ambitious longer-dated asset in a food-allergy market with substantial unmet need. Investors should treat those as call options rather than near-term earnings drivers.
Competitive backdrop
Allergy immunotherapy is a concentrated field. Allergy Therapeutics competes against larger specialists such as Stallergenes Greer and ALK-Abelló, both of which command greater scale and deeper resources. The group's differentiation has traditionally been its short-course, adjuvanted formulations, which require fewer injections than conventional regimes. Grassmuno's approval under the TAV framework gives it a defined regulatory position in Germany, the region's most valuable allergy market, but the competitive intensity means pricing and reimbursement dynamics will bear watching.
Risks and uncertainties
The risks are not trivial. Guidance is guidance: the FY2026 revenue figure is an expectation ahead of audited results, and the FY2027 double-digit target depends on a single product delivering through its first full season. The balance-sheet improvement leans on a new £40m senior secured facility provided by Hayfin and the refinancing of prior shareholder loans, so leverage and financing costs now carry more weight in the story.
Operating losses and negative equity have featured in recent reporting, and the shares have fallen sharply over the past year, leaving the market plainly sceptical. Currency swings, rebate pressures, the pace of the German transition and any slippage in supply reliability could all undercut the recovery narrative.
Milestones to watch
Several near-term markers will test the thesis. Audited full-year results should confirm the guided revenue and, more importantly, the trajectory of losses and cash burn. The conclusion of the TAV transition in October 2026, the early read on Grassmuno's first full season and any further colour on the previously mooted evaluation of a Hong Kong dual listing all sit on the calendar. Pipeline updates on VLP Peanut would speak to the longer-term valuation case.
Our reading
Allergy Therapeutics has given the market a coherent recovery story: stabilised sales, an accelerating second half, a flagship launch with a full season still to come and a balance sheet that no longer looks acutely stretched. That is a materially better position than a year ago, and the double-digit FY2027 ambition gives investors a clear yardstick against which to judge execution.
The counterweight is that much of this remains prospective. Reported growth is still modest at constant currency, the financing that repaired the balance sheet adds obligations of its own, and the depressed share price signals real doubt. On our neutral reading, FY2026 looks less like a finish line than a foundation, and the burden now falls on Grassmuno and the German transition to convert guidance into delivered results.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...